SG10201505700QA - Process of producing cycloalkylcarboxamido-indole compounds - Google Patents

Process of producing cycloalkylcarboxamido-indole compounds

Info

Publication number
SG10201505700QA
SG10201505700QA SG10201505700QA SG10201505700QA SG10201505700QA SG 10201505700Q A SG10201505700Q A SG 10201505700QA SG 10201505700Q A SG10201505700Q A SG 10201505700QA SG 10201505700Q A SG10201505700Q A SG 10201505700QA SG 10201505700Q A SG10201505700Q A SG 10201505700QA
Authority
SG
Singapore
Prior art keywords
indole compounds
cycloalkylcarboxamido
producing
producing cycloalkylcarboxamido
indole
Prior art date
Application number
SG10201505700QA
Other languages
English (en)
Inventor
Gerald J Tanoury
Cristian Harrison
Benjamin Joseph Littler
Peter Jamison Rose
Robert Michael Hughes
Young Chun Jung
David Andrew Siesel
Elaine Chungmin Lee
Daniel T Belmont
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG10201505700QA publication Critical patent/SG10201505700QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/74—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG10201505700QA 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds SG10201505700QA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US32705710P 2010-04-22 2010-04-22
US32709510P 2010-04-22 2010-04-22
US32709910P 2010-04-22 2010-04-22
US32709110P 2010-04-22 2010-04-22
US32949310P 2010-04-29 2010-04-29
US32950010P 2010-04-29 2010-04-29
US32951010P 2010-04-29 2010-04-29
US33387010P 2010-05-12 2010-05-12

Publications (1)

Publication Number Publication Date
SG10201505700QA true SG10201505700QA (en) 2015-08-28

Family

ID=44278819

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2012078374A SG184987A1 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
SG10201505700QA SG10201505700QA (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds
SG10201913594UA SG10201913594UA (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012078374A SG184987A1 (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913594UA SG10201913594UA (en) 2010-04-22 2011-04-21 Process of producing cycloalkylcarboxamido-indole compounds

Country Status (18)

Country Link
US (4) US9035072B2 (fr)
EP (3) EP2560954B1 (fr)
JP (4) JP2013525371A (fr)
KR (3) KR101984225B1 (fr)
CN (2) CN105130948A (fr)
AR (1) AR081333A1 (fr)
AU (2) AU2011242712B2 (fr)
BR (1) BR112012027056B8 (fr)
CA (2) CA2797118C (fr)
ES (2) ES2858351T3 (fr)
HK (2) HK1218419A1 (fr)
IL (3) IL222539A0 (fr)
MX (3) MX342288B (fr)
NZ (2) NZ603721A (fr)
RU (2) RU2569678C2 (fr)
SG (3) SG184987A1 (fr)
TW (3) TWI620744B (fr)
WO (1) WO2011133751A2 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1664006A2 (fr) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs a cassette de liaison a l'atp
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2810655C (fr) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
EP1912983B1 (fr) 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
SI2395002T1 (sl) 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
EP3708564A1 (fr) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated Une forme solide de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2007756B1 (fr) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs de cassettes de liaison de l'atp
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
CA2696298C (fr) 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
ES2658064T3 (es) 2007-11-16 2018-03-08 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
PL2639223T3 (pl) 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych
CA2931134C (fr) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Derives heteroaryles convenant comme modulateurs du cftr
EP2980077B1 (fr) 2008-03-31 2020-05-06 Vertex Pharmaceuticals Incorporated Dérivés de pyridyle comme modulateurs cftr
WO2010037066A2 (fr) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Unités posologiques d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
KR101852173B1 (ko) 2009-03-20 2018-04-27 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2604105T3 (es) * 2010-03-25 2017-03-03 Vertex Pharmaceuticals Incorporated Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida
CN102933206A (zh) 2010-04-07 2013-02-13 弗特克斯药品有限公司 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
MX342288B (es) * 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
IN2014KN00885A (fr) * 2011-11-08 2015-10-02 Vertex Pharma
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
BR112017014213A2 (pt) * 2014-12-31 2018-04-10 Auspex Pharmaceuticals Inc moduladores de ciclopropanocarboxamida do regulador da condutância transmembrana da fibrose cística.
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
WO2016160945A1 (fr) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Vx-661 deutéré
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
KR20180102590A (ko) * 2015-12-24 2018-09-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
WO2017180794A1 (fr) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
DK3551622T3 (da) 2016-12-09 2020-11-23 Vertex Pharma Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren
WO2018183367A1 (fr) 2017-03-28 2018-10-04 Van Goor Fredrick F Méthodes de traitement de fibrose kystique chez des patients ayant des mutations à fonction résiduelle
EP3634402A1 (fr) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
CA3068609A1 (fr) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions et methodes de traitement de la fibrose kystique
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069225A1 (fr) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methodes de traitement de la fibrose kystique
AR112467A1 (es) 2017-08-02 2019-10-30 Vertex Pharma Procesos para preparar compuestos
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
WO2020102346A1 (fr) 2018-11-14 2020-05-22 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
CA3067611A1 (fr) 2019-01-15 2020-07-15 Apotex Inc. Procede de preparation de tezacaftor et intermediaires connexes
WO2020214921A1 (fr) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Formes solides de modulateurs de cftr
KR102389717B1 (ko) * 2019-06-19 2022-04-25 주식회사 엘지화학 인돌 또는 인다졸 화합물의 제조방법
KR102389716B1 (ko) * 2019-06-19 2022-04-25 주식회사 엘지화학 인돌 또는 인다졸 화합물의 제조방법
JP2022544383A (ja) 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレータの結晶形態
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
JP2022545359A (ja) 2019-08-14 2022-10-27 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子モジュレーター
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
CN113121358A (zh) * 2019-12-31 2021-07-16 阜新金特莱氟化学有限责任公司 2-溴-5-氟-4-硝基苯胺的制备方法
CN111187197B (zh) * 2020-01-13 2021-10-01 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体的合成方法
EP4099991A1 (fr) * 2020-02-05 2022-12-14 Laurus Labs Limited Nouveaux procédés de préparation de tézacaftor
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP4196221A1 (fr) 2020-08-13 2023-06-21 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
EP4225750A1 (fr) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2022076620A1 (fr) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US20230373939A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230416275A1 (en) 2020-10-07 2023-12-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JP2023545081A (ja) 2020-10-07 2023-10-26 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子モジュレーター
EP4225748A1 (fr) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
JP2023545762A (ja) 2020-10-07 2023-10-31 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
CA3197683A1 (fr) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
US20230382924A1 (en) 2020-10-07 2023-11-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225762A1 (fr) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
JP2023552828A (ja) 2020-12-10 2023-12-19 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
CN113657599B (zh) * 2021-08-20 2024-05-28 北京航空航天大学 事故因果推理方法、装置、电子设备及可读存储介质
WO2023150236A1 (fr) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
WO2023154291A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2023196429A1 (fr) 2022-04-06 2023-10-12 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2023224931A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
WO2023224924A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation

Family Cites Families (328)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605382A (nl) * 1975-06-04 1976-12-07 Sumitomo Chemical Co Werkwijze voor het bereiden van indoolderivaten.
JPS5328173A (en) * 1976-08-06 1978-03-16 Zenyaku Kogyo Kk Novel phenylmethanenitro compound and its preparation
DE2735133C2 (de) 1977-08-04 1981-10-15 Universität Karlsruhe Institut für Elektrotechnische Grundlagen der Informatik, 7500 Karlsruhe Speicherzelle für zerstörungsfreies Auslesen mit 2 Josephson-Kontakten
US4138397A (en) 1978-02-27 1979-02-06 Richardson-Merrell Inc. 6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPS61103861A (ja) * 1984-10-27 1986-05-22 Nitto Kasei Kk アリ−ル置換シアン酢酸エステルの製造方法
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
WO1998047868A1 (fr) 1997-04-18 1998-10-29 Smithkline Beecham Plc Derives d'uree contenant un heterocycle utilises comme antagonistes des recepteurs 5ht1a, 5ht1b et 5ht¿1d?
ES2247707T3 (es) 1997-06-21 2006-03-01 Roche Diagnostics Gmbh Derivados del acido barbiturico con actividad antimetastasica y antitumoral.
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
AU740745B2 (en) 1997-12-11 2001-11-15 Biochem Pharma Inc. Antiviral compounds
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
EP1035115B1 (fr) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
WO2001019830A1 (fr) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATEURS DE PROTEINE TYROSINE PHOSPHATASE (PTPases)
US7019026B1 (en) 1999-09-10 2006-03-28 Novo Nordisk A/S Modulators of Protein Tyrosine Phosphatases (PTPases)
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
DE10038019A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6562989B2 (en) * 2000-08-07 2003-05-13 Yale University Catalyst for aromatic C—O, C—N, and C—C bond formation
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US6550895B1 (en) 2000-10-20 2003-04-22 Silverbrook Research Pty Ltd Moving nozzle ink jet with inlet restriction
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1383799A4 (fr) 2001-04-10 2008-08-06 Transtech Pharma Inc Sondes, systemes et procedes pour la decouverte de medicaments
ATE449763T1 (de) 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
WO2003007945A1 (fr) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
WO2003041649A2 (fr) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Derives cyanoalkylamino utilises comme inhibiteurs de la protease
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2003093498A1 (fr) 2002-04-29 2003-11-13 The Ohio State University Inhibition des proteine-tyrosine-phosphatases et des domaines sh2 par un mimetique de phosphotyrosine neutre
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
CN1688577A (zh) 2002-09-18 2005-10-26 小野药品工业株式会社 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
EA009847B1 (ru) 2002-09-30 2008-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
JP2004131393A (ja) 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
US20050215614A1 (en) 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
FR2846327B1 (fr) 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
WO2004041277A1 (fr) 2002-11-01 2004-05-21 Merck & Co., Inc. Derives de carbonylamino-benzimidazole utilises comme modulateurs du recepteur androgene
DE10251019A1 (de) 2002-11-02 2004-05-19 Aventis Pharma Deutschland Gmbh Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
KR101050680B1 (ko) 2002-11-02 2011-07-21 사노피-아벤티스 도이칠란트 게엠베하 콜라게네이즈의 선택적인 억제를 위한 신규한피리미딘-4,6-디카복스아미드
US20040146941A1 (en) 2002-11-04 2004-07-29 Biliang Zhang Chemical encoding technology for combinatorial synthesis
WO2004056744A1 (fr) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
DE10300017A1 (de) 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Selektive MMP 13 Inhibitoren
US20040229955A1 (en) 2003-01-08 2004-11-18 Andersen Niels H. Antibacterial agents
US6933311B2 (en) 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ATE450533T1 (de) 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
DE10306941A1 (de) 2003-02-18 2004-08-26 Merck Patent Gmbh Benzofuranoxyethylamine
US20050113423A1 (en) 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
DE10315377A1 (de) 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
US20050164951A1 (en) 2003-04-03 2005-07-28 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
MXPA05010444A (es) 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
HUE031794T2 (en) 2003-04-11 2017-08-28 Ptc Therapeutics Inc 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP1646615B1 (fr) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp
AU2004253541B2 (en) 2003-06-27 2010-10-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Amphiphilic pyridinium compounds, method of making and use thereof
US20050113576A1 (en) 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
NZ544935A (en) 2003-08-15 2009-08-28 Lundbeck & Co As H Cyclopropyl derivatives as NK3 receptor antagonists
EP1664006A2 (fr) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs a cassette de liaison a l'atp
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
RU2006115602A (ru) 2003-10-08 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы переносчиков атф-связывающих кассет
WO2005037802A1 (fr) * 2003-10-16 2005-04-28 Sankyo Company, Limited Derive de 5-arylpyrimidine
WO2005040135A1 (fr) 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. Medicament antistress et usage medical correspondant
RU2006120549A (ru) 2003-11-14 2007-12-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (fr) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de type cassette de liaison a l'atp
WO2005074650A2 (fr) 2004-02-02 2005-08-18 Ambrx, Inc. Polypeptides a faisceau a quatre helices (4hb) humains modifies, et leur utilisation
BRPI0509282A (pt) 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
US20050222271A1 (en) 2004-03-31 2005-10-06 Le Huang Novel amorphous form of memantine hydrochloride
FR2868417B1 (fr) 2004-04-02 2006-06-23 Rhodia Chimie Sa Procede de formation d'une liaison carbone-carbone
WO2005117514A2 (fr) 2004-06-01 2005-12-15 Tm Bioscience Corporation Procédé de détection des mutations associées à la fibrose cystique
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CA2810655C (fr) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
EP2363129A1 (fr) 2004-10-13 2011-09-07 PTC Therapeutics, Inc. Composes de suppression de non-sens et procedes de leur utilisation
CA2584342C (fr) 2004-10-20 2013-04-30 The Regents Of The University Of California Inhibiteurs ameliores de l'epoxyde hydrolase soluble
EP1829863A4 (fr) 2004-11-26 2009-04-22 Takeda Pharmaceutical Derive d'acide arylalcanoique
MX2007010112A (es) 2005-02-25 2007-10-12 Ono Pharmaceutical Co Compuesto indol y uso del mismo.
US8242149B2 (en) 2005-03-11 2012-08-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BRPI0608453A2 (pt) 2005-03-18 2009-12-29 Univ California compostos tendo atividade na correção de processamento de cftr mutante e usos destes
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US20100120789A1 (en) 2005-03-24 2010-05-13 Nigel Vicker Compound
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
SI2348022T1 (sl) 2005-03-28 2013-05-31 Toyama Chemical Co., Ltd. Postopek proizvodnje 1-(3-(2-(1-benzotiofen-5-il)etoksi)propil)azetidin-3-ola ali soli le-tega
JP2006282534A (ja) 2005-03-31 2006-10-19 Fuji Photo Film Co Ltd アミド類の製造方法
ES2390804T3 (es) 2005-04-08 2012-11-16 Ptc Therapeutics, Inc. Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido
JP2008537953A (ja) 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
EP1891018B1 (fr) 2005-05-24 2011-11-16 Vertex Pharmaceuticals, Inc. Modulateurs des transporteurs de cassette de liaison a l'atp
EP1912983B1 (fr) 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
ZA200802172B (en) 2005-08-11 2009-06-24 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
BRPI0616459A2 (pt) * 2005-09-29 2011-06-21 Wyeth Corp compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto
JP2009511494A (ja) 2005-10-06 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
WO2007056143A2 (fr) 2005-11-02 2007-05-18 Cytokinetics, Inc. Entites et compositions chimiques et methodes associees
SI2395002T1 (sl) 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
US8030305B2 (en) * 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
AU2006331614A1 (en) 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of ABC transporters
EP1974212A1 (fr) 2005-12-27 2008-10-01 Vertex Pharmaceuticals Incorporated Composes utiles dans les bio-essais cftr et leurs procedes
CN103214450B (zh) 2005-12-28 2016-10-05 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物
EP3708564A1 (fr) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated Une forme solide de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
GEP20125378B (en) 2006-03-20 2012-01-10 Vertex Pharma Pharmaceutical compositions
EP2001498A4 (fr) 2006-03-20 2013-01-23 Vertex Pharma Compositions pharmaceutiques
CA2681639A1 (fr) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Composes et methodes pour traitement de troubles associes a un stress du reticulum endoplasmique
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP2007756B1 (fr) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs de cassettes de liaison de l'atp
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
EP2035005A4 (fr) 2006-06-09 2011-07-06 Kemia Inc Thérapie à base d'inhibiteurs de cytokine
WO2008020227A2 (fr) 2006-08-17 2008-02-21 Astrazeneca Ab Composés chimiques
WO2008029168A2 (fr) 2006-09-08 2008-03-13 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
WO2008029152A2 (fr) 2006-09-08 2008-03-13 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
JP2010507577A (ja) 2006-10-23 2010-03-11 エスジーエックス ファーマシューティカルズ、インコーポレイテッド トリアゾロピリダジンタンパク質キナーゼモジュレーター
WO2008127399A2 (fr) 2006-11-03 2008-10-23 Vertex Pharmaceuticals Incorporated Dérivés d'azaindole comme modulateurs de cftr
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008064259A2 (fr) 2006-11-21 2008-05-29 Biokey, Inc. Composition de dispersion solide
WO2008065732A1 (fr) 2006-11-27 2008-06-05 Nippon Polyurethane Industry Co., Ltd. Procédé de production d'un mélange à base d'isocyanate modifié contenant une liaison allophanate et une liaison isocyanurate
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
EP2167058B1 (fr) 2007-06-18 2015-08-12 University Of Louisville Research Foundation, Inc. Famille d'inhibiteurs de pfkfb3 à activités anti-néoplasiques
US8557823B2 (en) 2007-06-18 2013-10-15 Advanced Cancer Therapeutics, Llc Family of PFKFB3 inhibitors with anti-neoplastic activities
SI2178865T1 (sl) 2007-07-19 2015-11-30 Lundbeck, H., A/S 5-členski heterociklični amidi in sorodne spojine
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
CA2696298C (fr) 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
EP2222304A2 (fr) 2007-09-14 2010-09-01 Vertex Pharmaceuticals Incorporated Formes solides de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoleine-3-carboxamide
EP2201010B1 (fr) 2007-09-14 2013-11-06 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
ES2658064T3 (es) 2007-11-16 2018-03-08 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
US8227463B2 (en) 2007-11-22 2012-07-24 Zenyaku Kogyo Kabushiki Kaisha Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
PL2639223T3 (pl) 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych
EA201070699A1 (ru) 2007-12-07 2011-02-28 Вертекс Фармасьютикалз Инкорпорейтед Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2231671B1 (fr) 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulateurs de régulateur de conductance transmembranaire de fibrose cystique
US20090247521A1 (en) 2007-12-28 2009-10-01 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
CA2931134C (fr) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Derives heteroaryles convenant comme modulateurs du cftr
EP2980077B1 (fr) 2008-03-31 2020-05-06 Vertex Pharmaceuticals Incorporated Dérivés de pyridyle comme modulateurs cftr
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
US20090270452A1 (en) 2008-04-18 2009-10-29 Arete Therapeutics, Inc. Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP2328618B1 (fr) 2008-08-13 2017-11-29 Vertex Pharmaceuticals Incorporated Composition pharmaceutique de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4- oxoquinoline-3-carboxamide et son administration
WO2010028159A2 (fr) 2008-09-04 2010-03-11 Georgetown University Amination de c-h catalysée par un métal de transition à l'aide d'amines non activées
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
WO2010037066A2 (fr) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Unités posologiques d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
US20110257223A1 (en) * 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
SI2349263T1 (sl) * 2008-10-23 2014-09-30 Vertex Pharmaceuticals Incorporated Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti
NZ592687A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
NZ592504A (en) 2008-10-23 2013-04-26 Vertex Pharma Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
NZ609962A (en) 2008-11-06 2014-11-28 Vertex Pharma Modulators of atp-binding cassette transporters
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
EP2384328B1 (fr) 2008-11-27 2013-02-13 Boehringer Ingelheim International GmbH Derives de 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene, compositions pharmaceutiques contenant ces composes, leur utilisation et procede pour leur preaparation
CA2745119A1 (fr) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c de type ns5a
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
KR20100101054A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
DK2408749T3 (en) 2009-03-20 2018-08-13 Vertex Pharma CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS
KR101852173B1 (ko) 2009-03-20 2018-04-27 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
GB0905641D0 (en) 2009-04-01 2009-05-13 Serodus As Compounds
EA022629B1 (ru) 2009-04-16 2016-02-29 Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii Имидазопираны для применения в качестве ингибиторов киназ
WO2011005355A1 (fr) 2009-05-07 2011-01-13 Achaogen, Inc. Combinaisons comprenant un inhibiteur de lpxc et un antibiotique à utiliser dans le traitement d'infections induites par des bactéries à gram négatif
EP3632899A1 (fr) 2009-05-29 2020-04-08 RaQualia Pharma Inc. Dérivés de carboxamide substitués d'aryle en tant que bloqueurs canaux calciques ou sodiques
EP2264012A1 (fr) 2009-06-03 2010-12-22 Bayer CropScience AG Hétéroarylamidine et son utilisation en tant que fongicide
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
WO2011029832A1 (fr) 2009-09-09 2011-03-17 Vifor (International) Ag Nouveaux antagonistes de la thiazol- et de l'oxazol-hepcidine
KR20120083416A (ko) 2009-09-17 2012-07-25 버텍스 파마슈티칼스 인코포레이티드 아자비시클릭 화합물의 제조 방법
SG179112A1 (en) 2009-09-18 2012-04-27 Univ Nanyang Tech Process of forming an amide
EP2813227A1 (fr) * 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques
CA2778492A1 (fr) 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Procede de preparation de modulateurs de regulateur de conductance transmembranaire de fibrose kystique
WO2011050220A1 (fr) 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Formes solides de n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluorométhyl)phényl)-4-oxo-5-(trifluorométhyl)-1,4-dihydroquinoline-3-carboxamide
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
CN104592205A (zh) 2010-03-01 2015-05-06 Gtx公司 用于治疗癌的化合物
WO2011115892A1 (fr) 2010-03-15 2011-09-22 Griffin Patrick R Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque
US8471029B2 (en) 2010-03-19 2013-06-25 Vertex Pharmaceutical Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8802868B2 (en) * 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2604105T3 (es) 2010-03-25 2017-03-03 Vertex Pharmaceuticals Incorporated Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida
CN102933206A (zh) 2010-04-07 2013-02-13 弗特克斯药品有限公司 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
CA2796602A1 (fr) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
AU2011242452A1 (en) * 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
MX342288B (es) * 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
WO2011133956A1 (fr) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
EP2787043B1 (fr) 2010-04-30 2018-03-21 Total Marketing Services Utilisation de dérivés organogelateurs dans des compositions bitumineuses pour améliorer leur résistance aux agressions chimiques
NZ603386A (en) 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
AR081920A1 (es) 2010-05-20 2012-10-31 Vertex Pharma Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica
DK2571506T3 (en) 2010-05-20 2017-08-28 Cempra Pharmaceuticals Inc PROCEDURES FOR THE MANUFACTURE OF MACROLIDES AND KETOLIDES AND INTERMEDIATES
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US20120149708A1 (en) 2010-06-17 2012-06-14 George Mason University Modulators of viral transcription, and methods and compositions therewith
WO2012016133A2 (fr) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
RU2013112937A (ru) * 2010-08-23 2014-09-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение
RU2013113627A (ru) 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
WO2012049555A1 (fr) 2010-10-13 2012-04-19 Lupin Limited Composés spirocycliques en tant que modulateurs de canaux sodiques dépendants du voltage
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2012079583A1 (fr) 2010-12-15 2012-06-21 Aarhus Universitet Système permettant la libération contrôlée de co gazeux pour réactions de carbonylation
CA2827392A1 (fr) 2011-02-24 2012-08-30 Emory University Compositions antagonistes de noggine pour ossification et procedes associes a celles-ci
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
CN102731492B (zh) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2013005057A1 (fr) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Nouveaux composés
SG2014013767A (en) 2011-09-09 2014-05-29 Lantheus Medical Imaging Inc Compositions, methods, and systems for the synthesis and use of imaging agents
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
EP2755652B1 (fr) 2011-09-16 2021-06-02 Novartis AG Hétérocyclyle carboxamides n-substitués
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
EP2773349A1 (fr) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Utilisation de (n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) pour le traitement des maladies associées au gène cftr
US20140127901A1 (en) * 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
IN2014KN00885A (fr) * 2011-11-08 2015-10-02 Vertex Pharma
WO2013086131A1 (fr) 2011-12-06 2013-06-13 The Trustees Of The University Of Pennsylvania Inhibiteurs ciblant la grippe a pharmacorésistante
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
EP2606726A1 (fr) 2011-12-21 2013-06-26 Bayer CropScience AG Dérivés de trifluoroéthylsulfure substitués par du N-arylamidine en tant qu'acaricides et insecticides
SG10201606135TA (en) 2012-01-25 2016-09-29 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
EP2834313A1 (fr) 2012-04-03 2015-02-11 3M Innovative Properties Company Composition pouvant être réticulée comportant des générateurs de photobase
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9228101B2 (en) 2012-04-26 2016-01-05 Xerox Corporation Rapidly crystallizing phase change inks and methods for forming the same
US8888905B2 (en) 2012-04-26 2014-11-18 Xerox Corporation Fast crystallizing crystalline-amorphous ink compositions and methods for making the same
US20130284054A1 (en) 2012-04-26 2013-10-31 Xerox Corporation Rapid solidifying crystalline-amorphous inks
US9528016B2 (en) 2012-04-26 2016-12-27 Xerox Corporation Phase change inks comprising crystalline amides
CA2813472A1 (fr) 2012-04-26 2013-10-26 Xerox Corporation Encres amorphes cristallines a solidification rapide
GB2502624A (en) 2012-06-01 2013-12-04 Univ East Anglia Phosphoramide and phosphoramide-based catalysts and their use in intermolecular aziridination
EP2858645A1 (fr) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques pour le traitement des troubles à médiation par cftr
US8889857B2 (en) 2012-06-08 2014-11-18 Massachusetts Institute Of Technology Phosphine-ligated palladium sulfonate palladacycles
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
WO2014002106A1 (fr) 2012-06-25 2014-01-03 Cadila Healthcare Limited Nouveaux composés pour le traitement de la dyslipidémie et de maladies associées
WO2014011050A1 (fr) 2012-07-12 2014-01-16 Proqr Therapeutics B.V. Remplacement d'exons par des arn artificiels stabilisés
KR20150037968A (ko) 2012-07-12 2015-04-08 프로큐알 테라퓨틱스 엔.브이. 살아있는 세포 내에 존재하는 목적 rna 분자의 서열을 변화시키기 위한 올리고뉴클레오타이드
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
CN110776447A (zh) 2012-09-20 2020-02-11 坦普尔大学 取代的烷基二芳基衍生物、制备方法和用途
WO2014068893A1 (fr) 2012-10-29 2014-05-08 コニカミノルタ株式会社 Film à différence de phase, plaque de polarisation circulaire, et dispositif de formation d'image
JP6302923B2 (ja) 2012-11-02 2018-03-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｆｔｒが媒介する疾患の処置のための医薬組成物
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
JP6146990B2 (ja) 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
MX366041B (es) 2012-11-20 2019-06-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos y composiciones y método de uso de los mismos.
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2929346A1 (fr) 2012-12-05 2015-10-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Diagnostic de fibrose kystique
US20140158127A1 (en) 2012-12-07 2014-06-12 Parion Sciences, Inc. Nasal cannula for delivery of aerosolized medicaments
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US20140296164A1 (en) 2013-03-29 2014-10-02 Calista Therapeutics, Inc. Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
CA2911453C (fr) 2013-05-07 2021-08-03 Galapagos Nv Nouveaux composes et leurs compositions pharmaceutiques pour le traitement de la mucoviscidose.
US20160194299A1 (en) 2013-05-24 2016-07-07 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
US20160151335A1 (en) 2013-06-26 2016-06-02 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
PT3030568T (pt) 2013-08-08 2018-12-24 Galapagos Nv Tieno[2,3-c]piranos como moduladores de cftr
JP6472807B2 (ja) 2013-09-12 2019-02-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 嚢胞性線維症の処置のための方法及び医薬組成物
CA2924527C (fr) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Composes destines au traitement du cancer de la prostate
US9353078B2 (en) 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
WO2015054337A1 (fr) 2013-10-09 2015-04-16 Emory University Catalyseurs de couplage hétérocyclique et procédés associés à ceux-ci
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
KR20150062652A (ko) 2013-11-29 2015-06-08 삼성전자주식회사 초음파 감응성 리포좀, 그를 포함한 약제학적 조성물 및 그를 이용하여 개체의 체내에 활성제를 전달하는 방법
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN106458856A (zh) 2014-03-07 2017-02-22 约翰霍普金斯大学 组蛋白赖氨酸特异性的脱甲基酶(lsd1)和组蛋白脱乙酰基酶(hdac)的抑制剂
JP2015172005A (ja) 2014-03-11 2015-10-01 国立大学法人 東京大学 鉄触媒によるカップリング化合物の製造方法
WO2015138934A1 (fr) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité cftr
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
JP5932881B2 (ja) * 2014-05-08 2016-06-08 株式会社フジクラ マルチコアファイバ及びそのマルチコアファイバの製造方法
HUE048020T2 (hu) 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
ES2824105T3 (es) 2014-05-16 2021-05-11 Olaplex Inc Formulaciones y métodos de tratamiento de queratina
CA2949511A1 (fr) 2014-05-19 2015-11-26 Merial, Inc. Composes anthelmintiques
WO2015187905A1 (fr) 2014-06-05 2015-12-10 Merck Patent Gmbh Nouveaux dérivés de quinoléine et leur utilisation dans des maladies neurodégénératives
EP3157917B1 (fr) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016025448A2 (fr) 2014-08-13 2016-02-18 Akeso Biomedical, Inc. Composés et compositions antimicrobiens ainsi que leurs utilisations
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
US10266526B2 (en) 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
WO2016050209A1 (fr) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 Dérivé de polyéthylèneglycol hétérofonctionalisé, procédé de préparation et substance d'origine biologique
WO2016050210A1 (fr) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 Dérivé de polyéthylène glycol multifonctionnalisé et son procédé de préparation
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
WO2016050208A1 (fr) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 Substance d'origine biologique modifiée par un dérivé du polyéthylèneglycol multifonctionnalisé
US9855249B2 (en) 2014-10-02 2018-01-02 Flatley Discovery Lab, Llc Isoxazole compounds and methods for the treatment of cystic fibrosis
CN107106546A (zh) 2014-10-06 2017-08-29 弗拉特利发现实验室有限责任公司 三唑并吡啶化合物和用于治疗囊性纤维化的方法
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
EP3204010A1 (fr) 2014-10-08 2017-08-16 Nivalis Therapeutics, Inc. Méthodes de traitement de la mucoviscidose
US20160108406A1 (en) 2014-10-08 2016-04-21 University Of Iowa Research Foundation Method of regulating cftr expression and processing
GB201418892D0 (en) 2014-10-23 2014-12-10 Proqr Therapeutics B V DNA editing
EP3212201B1 (fr) 2014-10-28 2022-10-19 BCI Pharma Inhibiteurs de la kinase nucléoside
CA3191010A1 (fr) 2014-10-31 2016-05-06 AbbVie Global Enterprises Ltd. Chromanes substitues et methode d'utilisation
EP3212184B1 (fr) 2014-10-31 2020-04-01 AbbVie Overseas S.à r.l. Benzotétrahydropyranes substitués et leur utilisation
WO2016086015A1 (fr) 2014-11-25 2016-06-02 University Of Rochester Catalyseurs à base de myoglobine pour réactions de transfert de carbène
WO2016086136A1 (fr) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Conjugués de cystéamine d'acide gras de modulateurs de cftr et leur utilisation dans le traitement de troubles médicaux
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016105484A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Dérivés d'amide 5-(hétéro)arylpyrazol-3-carboxylique ou d'amide 1-(hétéro)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique
WO2016105468A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105477A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Dérivés d'amides 5-phényl- ou 5-hétéroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique
CA2971121A1 (fr) 2014-12-24 2016-06-30 Kither Biotech S.R.L. Nouveau peptide inhibiteur de .gamma. de pi3k pour le traitement de maladies du systeme respiratoire
BR112017014213A2 (pt) 2014-12-31 2018-04-10 Auspex Pharmaceuticals Inc moduladores de ciclopropanocarboxamida do regulador da condutância transmembrana da fibrose cística.
WO2016107603A1 (fr) 2015-01-01 2016-07-07 成都贝斯凯瑞生物科技有限公司 Dérivés hétérocycliques contenant de l'azote substitué et leurs applications
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2016160945A1 (fr) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Vx-661 deutéré

Also Published As

Publication number Publication date
TWI518082B (zh) 2016-01-21
US20210238158A1 (en) 2021-08-05
HK1218419A1 (zh) 2017-02-17
AU2016202569A1 (en) 2016-05-19
JP2019031570A (ja) 2019-02-28
TW201636337A (zh) 2016-10-16
CA2797118C (fr) 2021-03-30
RU2015145784A3 (fr) 2019-04-29
JP6484652B2 (ja) 2019-03-13
SG10201913594UA (en) 2020-02-27
KR101984225B1 (ko) 2019-05-30
ES2858351T3 (es) 2021-09-30
BR112012027056B1 (pt) 2021-08-24
NZ603721A (en) 2014-11-28
JP2015166382A (ja) 2015-09-24
RU2012149691A (ru) 2014-05-27
IL236209A0 (en) 2015-01-29
WO2011133751A9 (fr) 2012-02-16
JP2013525371A (ja) 2013-06-20
AU2016202569B2 (en) 2018-01-04
BR112012027056A2 (pt) 2017-08-08
CN103038214A (zh) 2013-04-10
JP6714673B2 (ja) 2020-06-24
KR20160045943A (ko) 2016-04-27
IL222539A0 (en) 2012-12-31
US9035072B2 (en) 2015-05-19
EP3381899A1 (fr) 2018-10-03
US20150218122A1 (en) 2015-08-06
NZ734535A (en) 2019-05-31
TW201204715A (en) 2012-02-01
EP3381899B1 (fr) 2021-01-06
AU2011242712A1 (en) 2012-11-08
CA2797118A1 (fr) 2011-10-27
MX342288B (es) 2016-09-23
IL236209B (en) 2019-09-26
IL268953A (en) 2019-10-31
TWI620744B (zh) 2018-04-11
JP2017071650A (ja) 2017-04-13
CN103038214B (zh) 2015-09-30
CN105130948A (zh) 2015-12-09
EP3045452A1 (fr) 2016-07-20
IL268953B (en) 2020-05-31
US20190210991A1 (en) 2019-07-11
AU2011242712B2 (en) 2016-01-28
KR20190061096A (ko) 2019-06-04
RU2569678C2 (ru) 2015-11-27
EP2560954B1 (fr) 2016-10-05
RU2745977C2 (ru) 2021-04-05
MX353408B (es) 2018-01-11
KR20130056244A (ko) 2013-05-29
TWI561518B (en) 2016-12-11
EP2560954A2 (fr) 2013-02-27
BR112012027056B8 (pt) 2021-09-08
WO2011133751A3 (fr) 2012-01-12
US20130324743A1 (en) 2013-12-05
MX2012012204A (es) 2012-12-05
AR081333A1 (es) 2012-08-08
WO2011133751A2 (fr) 2011-10-27
RU2015145784A (ru) 2019-01-11
US10071979B2 (en) 2018-09-11
ES2608474T3 (es) 2017-04-11
TW201612173A (en) 2016-04-01
HK1225721A1 (zh) 2017-09-15
CA3108488A1 (fr) 2011-10-27
SG184987A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
IL268953B (en) A process to form cycloalkylcarboxamido indole compounds
HK1178688A1 (en) Process for production of connected structure
IL248217B (en) A method for the production of inganol-3-englate
EP2581067A4 (fr) Procédé de production d'un produit absorbant
EP2609120A4 (fr) Procédé amélioré de préparation de sugammadex
EP2552874A4 (fr) Procédé pour la fabrication d'hexafluoro-2-butène
PL2531286T3 (pl) Sposób syntezy metanolu
EP2558432A4 (fr) Procédé de fabrication de tétrafluorooléfines
EP2528864A4 (fr) Procédé de production de composés cyclohexasilane
ZA201308852B (en) Process of making beta-hydroxyamino compounds
PL2571848T3 (pl) Sposób wytwarzania związków zawierających funkcyjne grupy nitrylowe
IL226677A (en) Beta-amyloid production compounds
HK1184787A1 (en) Production method of intermediate compound for synthesizing medicament
EP2623580A4 (fr) Procédé de production de beta-sialon
GB201004096D0 (en) Production of polyhydroalkanoates
IL222474A0 (en) Method of synthesis
HUE044066T2 (hu) Eljárás metilén-difenil-diizocianát elõállítására
EP2596007A4 (fr) Procédé de préparation de 17-désoxy-corticostéroïdes
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
EP2522648A4 (fr) Procede de production d'un compose de difluorocyclopropane
HK1171020A1 (en) Process for preparation of pyrimidinylpyrazole compounds
EP2537851A4 (fr) Procédé de préparation de composés b-glycosides
PT2390246T (pt) Processo para a preparação de aminaftona
GB201021753D0 (en) Process for producing 2-alkyl-cyclopent-2-enone compounds
IL226097A0 (en) A process for the production of derivatives of 4-carbonyloxyquinoline